Johnson & Johnson Form 4 insider transactions

Jennifer L. Taubert, EVP at Johnson & Johnson, reported multiple transactions involving common stock, restricted share units, performance share units, and stock options.

Timothy Schmid, EVP and WW Chair of MedTech at Johnson & Johnson, disclosed a series of equity transactions including RSU and PSU vestings, option exercises, and corresponding share sales for tax and profit realization.

Johnson & Johnson CEO Joaquin Duato reported multiple equity transactions, including vesting of restricted and performance share units and new option grants, primarily related to long-term incentive plans.

Johnson & Johnson's EVP of Global Corporate Affairs, Vanessa Broadhurst, reported multiple transactions involving common stock, including vesting of equity awards and a sale.

Johnson & Johnson's CFO, Joseph J. Wolk, reported the vesting of 37,463 Performance Share Units, reflecting achievement of long-term incentive goals.

Johnson & Johnson EVP Jennifer Taubert reported the vesting of 27,412 Performance Share Units, converting to common stock.

Johnson & Johnson's EVP and CIO, James D. Swanson, acquired 9,412 Performance Share Units, reflecting achievement of performance conditions.

Johnson & Johnson EVP Timothy Schmid's performance-based share units convert to common stock, reflecting achievement of award conditions.

Johnson & Johnson's EVP, Chief HR Officer, Kristen Mulholland, had 3,602 Performance Share Units certified, reflecting achievement of performance conditions.

Johnson & Johnson's EVP and Chief Legal Officer, Elizabeth Forminard, acquired 13,706 Performance Share Units following the certification of performance conditions.

Johnson & Johnson CEO Joaquin Duato reported the vesting of 73,054 Performance Share Units, reflecting the achievement of performance conditions.

Johnson & Johnson's VP Corporate Controller, Robert J. Decker, reported the vesting of 2,741 Performance Share Units.

Johnson & Johnson's EVP, Chief TO and Risk Officer, Kathryn E. Wengel, reported the vesting of 13,706 Performance Share Units.

Johnson & Johnson EVP Vanessa Broadhurst reported the vesting of 8,594 Performance Share Units, reflecting achievement of performance conditions.

Johnson & Johnson EVP Timothy Schmid exercised expiring stock options and subsequently sold shares to cover costs and taxes.

Johnson & Johnson's EVP, Chief HR Officer, Kristen Mulholland, exercised employee stock options and acquired common stock, while also selling shares to cover taxes and exercise costs.

Johnson & Johnson's EVP, Chief TO and Risk Officer, Kathryn E. Wengel, exercised stock options and sold shares to cover costs and taxes.

Johnson & Johnson's EVP, Chief Legal Officer, Elizabeth Forminard, exercised stock options and subsequently sold a portion of the acquired shares to cover tax liabilities.

Johnson & Johnson CEO and Chairman Joaquin Duato sold 100,000 shares of common stock for approximately $22.13 million on January 26, 2026, under a pre-arranged 10b5-1 trading plan.

Johnson & Johnson filed an amended Form 4 to disclose an additional sale of CVRx, Inc. common stock that was previously omitted.

Johnson & Johnson Director Eugene A. Woods acquired 185.533 Deferred Share Units as part of his compensation plan.

Johnson & Johnson Director Marillyn A. Hewson acquired 247.378 Deferred Share Units as part of a routine compensation plan.

Johnson & Johnson Director Daniel E. Pinto acquired 154.611 Deferred Share Units as part of a compensation deferral plan.

Johnson & Johnson Director John G. Morikis acquired 1,250 shares of common stock at $206.15 per share, increasing his direct beneficial ownership to 1,848.51 shares.

Johnson & Johnson, through its subsidiary, sold 6,337 shares of CVRx, Inc. common stock for a weighted average price of $10.03 per share.

Johnson & Johnson, through its subsidiary, reported the sale of 2,700 shares of CVRx, Inc. common stock in two transactions.

Johnson & Johnson, through its subsidiary JJDC, Inc., reported the sale of 1,000 shares of CVRx, Inc. common stock at a weighted average price of $10.00 per share.

Johnson & Johnson's subsidiary, JJDC, reported the sale of 52,532 shares of CVRx, Inc. common stock in early November 2025.

Johnson & Johnson EVP John C. Reed exercised stock options and sold common stock totaling 21,721 shares under a 10b5-1 plan.

Johnson & Johnson Director Marillyn A. Hewson acquired 280.788 Deferred Share Units as part of her compensation plan.